Swiss National Bank Sells 4,400 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Swiss National Bank cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,300 shares of the medical research company’s stock after selling 4,400 shares during the quarter. Swiss National Bank’s holdings in Charles River Laboratories International were worth $37,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. VisionPoint Advisory Group LLC boosted its position in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares during the period. Headlands Technologies LLC bought a new position in Charles River Laboratories International during the 3rd quarter valued at approximately $37,000. Operose Advisors LLC purchased a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $42,000. Venturi Wealth Management LLC grew its position in shares of Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after buying an additional 112 shares during the last quarter. Finally, Provence Wealth Management Group purchased a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $57,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of a number of research analyst reports. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Citigroup increased their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. UBS Group lifted their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.23.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $236.30 on Wednesday. The firm has a market capitalization of $12.17 billion, a PE ratio of 25.66, a PEG ratio of 1.83 and a beta of 1.44. The stock’s fifty day moving average is $251.61 and its 200 day moving average is $225.17. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.98 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock valued at $3,693,663 in the last quarter. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).